Based on encouraging preclinical studies demonstrating selective cytotoxicity in models with aneuploidy and CIN compared to diploid and genomically stable counterparts, several KIF18A inhibitors have progressed to evaluation in clinical trials [147]. The gene discussed is KIF18A; the disease is cervical squamous intraepithelial neoplasia.